IMPORTANCE Pericoronary adipose tissue (PCAT) computed tomography (CT) attenuation measured from coronary CT angiography (CTA) may be a promising metric in identifying high-risk plaques.
V ascular inflammation drives the development of coronary atherosclerosis and the rupture of vulnerable plaques, resulting in acute coronary syndrome (ACS). 1 Most high-risk plaques are nonobstructive and may not be detected with myocardial perfusion imaging tests, such as cardiac magnetic resonance imaging, single-photon emission computed tomography (CT), or echocardiography, as these stress tests assess stress-induced myocardial ischemia that is associated with obstructive coronary stenosis. 2 Standard noninvasive approaches are unable to measure coronary inflammation. 3 With fluorine 18-labeled ( 18 F) fluorodeoxyglucose positron emission tomography (PET), the detection of coronary inflammation is challenging and requires a PET scan with complex imaging protocols and processing. 4 Thus, the noninvasive detection and identification of inflamed coronary plaques remains challenging in clinical practice. 5 Epicardial coronary arteries are encased with pericoronary adipose tissue (PCAT). Recently, PCAT CT attenuation measured from CT angiography (CTA) was able to detect biopsy result-proven vascular inflammation in patients undergoing cardiac surgery. 6 To our knowledge, the association between high-risk plaque characteristics and PCAT CT attenuation in preintervention in vivo culprit lesions is unknown. We investigated the direct per-lesion association between anatomical plaque characteristics and inflammation by PCAT CT attenuation to improve vulnerable plaque identification in patients at risk of developing ACS.
Methods

Patients
The study design has been reported previously. 7 Institutional review board approval was obtained by the University of Erlangen and patients provided written informed consent. Additionally, the institutional review board approval for plaque quantification from the anonymized data was obtained at Cedars-Sinai Medical Center. In brief, we analyzed consecutive 19 patients who presented with a first ACS who underwent CTA that was followed by invasive angiography, and compared with controls with stable coronary artery disease (CAD) matched by age decile, sex, and risk factors; the controls also underwent coronary CTA followed by invasive angiography (eMethods in the Supplement).
Coronary Plaque Analysis
The CT imaging protocol and analysis of the coronary plaques were described previously (eMethods in the Supplement). 7 An experienced independent reader who was masked to the patient data analyzed all coronary segments with a lumen diameter of 2 mm or greater using semiautomated software (Autoplaque, version 2.0; Cedar-Sinai Medical Center 
Analysis of PCAT
For each lesion, PCAT was sampled radially outwards from the outer vessel wall and measured as voxels, with attenuation between −190 HU and −30 HU. Pericoronary adipose tissue CT attenuation was defined as the average CT attenuation of adipose tissue within the defined volume of interest ( Figure) . 6 We considered PCAT CT attenuation within an outer radial distance from the vessel wall equal to the average diameter of the lesion (Figure) . 6 
Statistical Analysis
The statistical analysis was performed using SPSS, version 24 (IBM). The presence of normal distribution for continuous data was tested with the Shapiro-Wilk test. A 2-sample t test or Wilcoxon rank sum test were applied to compare differences in continuous variables between groups, while Pearson or Spearman rank correlations were used to assess correlations between continuous variables. The association of plaque burden and PCAT CT attenuation with culprit lesions was assessed using a multivariable stepwise-backward logistic regression while adjusting for age, sex, and the number of risk factors. Optimal PCAT CT attenuation thresholds were determined from a receiver operator characteristic analysis, at the point in which the Youden J statistic (J=sensitivity +specificity− 1) was the highest. A 2-sided P value of <.05 was considered significant. 
Results
Patients
Per-Patient Coronary Plaque Analysis
Patients with ACS had less high-attenuation NCP burden compared with controls (Table 1) ; all other plaque burdens did not differ significantly between the 2 groups (Table 1) . Intermediate-and low-attenuation NCP volume, as well as the stenosis grade of lesions and CDD, were significantly higher in the ACS group (Table 1) .
Culprit vs Nonculprit Lesion Anatomical Characteristics
Plaque and PCAT measurements were performed in 19 culprit lesions of patients with ACS and in 105 nonculprit lesions in the ACS and control groups. Among patients with ACS, the low-attenuation NCP volume and the burdens of NCP, intermediate-attenuation NCP, and low-attenuation NCP were significantly higher in culprit vs nonculprit lesions ( Table 2 ; eFigure 1 in the Supplement). Culprit lesions had higher stenosis and CDD and shorter plaque length (Table 2) . Between patients with ACS and controls, low-attenuation NCP volume was significantly higher and high-attenuation NCP volume significantly lower in culprit lesions compared with the highest-grade stenosis in controls ( Table 2 ). The burden of total plaque, NCP, and intermediate-and lowattenuation NCP were significantly higher in culprit lesions (Table 2 ; eFigure 1 in the Supplement; 3-dimensional example of PCAT quantification shown in eFigure 3 of the Supplement). Culprit lesions also had higher maximal stenosis and CDD (Table 2) .
Culprit vs Nonculprit Lesion Inflammatory Characteristics
Pericoronary adipose tissue CT attenuation was significantly higher around culprit lesions compared with nonculprit lesions within patients with ACS and the highest-grade stenosis lesions of controls (eFigure 2 in the Supplement). Within all 74 lesions of the ACS group, PCAT CT attenuation had a receiver operating characteristic area under the curve of 0.70 (95% CI, 0.55-0.83) to identify culprit lesions, with the highest Youden index at the attenuation cutoff of −68.2 HU and an accuracy of 73%. The frequency of increased PCAT CT attenuation (≥−68.2 HU) was higher in culprit lesions compared with nonculprit lesions within patients with ACS (47.8% vs 15.7%; P = .003). Pericoronary adipose tissue CT attenuation of all 74 lesions within ACS group correlated more strongly with intermediate-attenuation NCP (r =0 . 3 9 3 ,P = .001) over lowattenuation NCP (r = 0.221, P = .06), high-attenuation NCP burden (r = −0.103, P = .38), and CP burden (r = 0.012, P = .92). In a multivariable logistic regression analysis, lowattenuation NCP burden (increase of 1%; odds ratio [OR], 1.43; 95% CI, 1.2-1.8; P < .001), intermediate-attenuation NCP burden (increase of 1%; OR, 1.27; 95% CI, 1.0-1.4; P < .01), and PCAT CT attenuation (1 HU increase; OR, 1.2; 95% CI, 1.0-1.3; P = .01) were related to the presence of culprit lesions.
Discussion
In our study, PCAT CT attenuation, a novel surrogate marker of coronary inflammation, was increased around culprit lesions compared with nonculprit lesions in patients with ACS and significantly stenosed lesions in stable CAD controls. Our results suggest that this imaging biomarker may help to identify vulnerable plaques.
Our findings of increased low-and intermediateattenuation NCP burden in culprit lesions compared with non-culprit lesions within the same patients suggest that these high-risk anatomical features can be identified noninvasively, which is consistent with prior studies. [8] [9] [10] [11] In intravascular ultrasonography studies, fibrofatty tissue/ intermediate-attenuation NCP and the necrotic core/lowattenuation NCP demonstrated lipid components, whereas fibrous tissue/high-attenuation NCP contained densely packed collagen. 12 Previous research using an invasive angiographic identification of culprit lesions also described a higher frequency of low-attenuation lesions (<30 HU) in patients with ACS than in stable CAD.
9,11
Antonopoulos et al 6 also described elevated PCAT CT attenuation around stented culprit lesions after myocardial infarction (n = 10) compared with stented, nonculprit lesions in patients with stable CAD (n = 11). 6 In contrast to our study, CTA was performed after percutaneous coronary intervention, the control group was not matched, and each culprit lesion was already stented when CTA was performed. It is unknown whether stented lesions are comparable with unstented lesions regarding the PCAT quantification because the percutaneous coronary intervention itself may affect the coronary inflammatory state and stent artifacts may hamper the accuracy of PCAT quantification. To our knowledge, ours is the first study to measure PCAT CT attenuation per lesion and systematically compare preintervention PCAT CT attenuation for culprit lesions with the highest-grade stenosed lesions in matched patients with stable CAD. To our knowledge, this is the first report of a higher frequency of increased PCAT CT attenuation (≥−68.2 HU) for culprit lesions compared with nonculprit lesions in ACS and the first attempt to provide potential cutoffs to distinguish between culprit and nonculprit lesions by CTA. Lu et al 13 reported that participants with high-risk plaques had lower epicardial adipose tissue CT attenuation compared with participants without high-risk plaques in noncontrast coronary calcium CT. By measuring PCAT thickness instead of PCAT CT attenuation in 103 patients undergoing CTA, catheterization, and intravascular ultrasonography, Okubo et al 14 showed that PCAT thickness instead of epicardial adipose tissue thickness was independently associated with vulnerable plaque features.
To our knowledge, this is the first report directly investigating the association between PCAT CT attenuation and NCP components of low-and intermediate-attenuation NCP burden in culprit lesions. The correlation with intermediateattenuation NCP in the underlying coronary segments provides a biological plausibility that PCAT CT attenuation describes biological processes that are associated with highrisk plaque characteristics instead of local vascular calcium deposition. 6 The association between PCAT CT attenuation and highrisk plaque characteristics may reflect vascular inflammation causing morphological changes of PCAT and may influence plaque stability. 6 Quantitative PCAT CT attenuation does not require extra protocols within routine CTA and may represent a dynamic imaging biomarker of vascular inflammation, enabling a simple, noninvasive identification of both coronary inflammation and vulnerable plaques from routine CTA. 
Limitations
This is a single-center and single-vendor study investigating a small, predominantly male population with CAD. As PCAT shares the blood supply with the coronary arteries, PCAT enhancement might be related to contrast media-induced lumen enhancement. Furthermore, the influence of different image acquisition parameters and different CT scanners on PCAT quantification should be investigated in future studies. Finally, our study lacked a second external cohort for validating PCAT attenuation thresholds. Coronary perivascular adipose tissue (PVAT), given its anatomic and biologic associations with the coronary arteries, may contribute greater insights into inflammation than structural CT metrics. Perivascular adipose tissue can release various bioactive molecules that target the coronary arteries, which have potent anti-inflammatory, antioxidative, and anticontractile properties. 3 Interestingly, this biochemical communication between PVAT and the arterial wall is bidirectional. In the setting of inflammation, coronary artery-released mediators alter the adipocyte maturation process in PVAT. 3, 4 In patients with CAD, these changes result in a pericoronary artery lipid gradient with a decreasing lipophilic content closer to the vessel wall. This differential gradient can be assessed by CT-measured attenuation. 4 The potential of this imaging target was described in a recent study by Antonopoulos and colleagues. 4 The authors present a 3-dimensional PVAT analysis that yielded an imaging metric for PVAT-a fat attenuation index (FAI; the average reduction of adipose tissue signal in a volume of interest). The authors validate FAI as a biomarker through extensive experiments that range from cell biology and gene expression studies to the CT imaging of explanted adipose tissue from patients to the serial imaging of patients. The FAI appears to increase around the coronary arteries of patients with CAD compared with controls and around myocardial infarction culprit lesions compared with stable lesions, and it resolves over time in culprit lesions. 4 Thus, the authors establish that human coronary arteries, under the influence of inflammation, exert a paracrine effect on adjacent PVAT that affects the local adipose tissue, the result of which can be imaged and quantified using routine CT imaging.
Conclusions
Other investigators have also provided insights with regard to the potential use of PVAT imaging. Perivascular adipose tissues that are adjacent to coronary segments with fibrous-rich and lipid-rich plaques tend to manifest greater attenuation. 5 Further, PVAT inflammation has been found to be increased in patients with vasospastic angina. 3 In a study of 103 patients who were undergoing CTA and subsequent percutaneous coronary intervention and intravascular ultrasonography (IVUS), measures of pericoronary adipose tissue were compared with those of EAT for identification of 
